Cost Effectiveness Analysis of Boceprevir (BOC) Added to Pegifn/Ribavirin (P/R) Versus Pegifn/Ribavirin (Current Standard of Care) for the Treatment of Patients with Genotype 1 Chronic Hepatitis C in Greece
2014 ◽
Vol 40
(6)
◽
pp. 657-675
◽
2013 ◽
Vol 11
(1)
◽
pp. 65-78
◽
2016 ◽
Vol 146
(2)
◽
pp. 61-64
◽
2015 ◽
Vol 18
(7)
◽
pp. 502-511
◽